282 related articles for article (PubMed ID: 24938475)
1. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.
Krug C; Wiesinger M; Abken H; Schuler-Thurner B; Schuler G; Dörrie J; Schaft N
Cancer Immunol Immunother; 2014 Oct; 63(10):999-1008. PubMed ID: 24938475
[TBL] [Abstract][Full Text] [Related]
2. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
3. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
4. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.
Krug C; Birkholz K; Paulus A; Schwenkert M; Schmidt P; Hoffmann N; Hombach A; Fey G; Abken H; Schuler G; Schuler-Thurner B; Dörrie J; Schaft N
Cancer Immunol Immunother; 2015 Dec; 64(12):1623-35. PubMed ID: 26515978
[TBL] [Abstract][Full Text] [Related]
5. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
Curran KJ; Pegram HJ; Brentjens RJ
J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
8. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
10. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
11. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
12. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
[TBL] [Abstract][Full Text] [Related]
13. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
14. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
[TBL] [Abstract][Full Text] [Related]
15. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
16. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
[TBL] [Abstract][Full Text] [Related]
17. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.
Frigault MJ; Lee J; Basil MC; Carpenito C; Motohashi S; Scholler J; Kawalekar OU; Guedan S; McGettigan SE; Posey AD; Ang S; Cooper LJ; Platt JM; Johnson FB; Paulos CM; Zhao Y; Kalos M; Milone MC; June CH
Cancer Immunol Res; 2015 Apr; 3(4):356-67. PubMed ID: 25600436
[TBL] [Abstract][Full Text] [Related]
18. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.
Panjwani MK; Smith JB; Schutsky K; Gnanandarajah J; O'Connor CM; Powell DJ; Mason NJ
Mol Ther; 2016 Sep; 24(9):1602-14. PubMed ID: 27401141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
